Embedded Files
Sustained Release of a Novel Non-Fibrate PPARα Agonist from Microparticles for Neuroprotection in Murine Models of Age-Related Macular Degeneration
Cui, Y.; Poudel, S.; Xu, N.; Zhou, K.; Cheng, R.; Liang, W.; Yuan, T.; Zhao, L.; Qin, C.; Stevens, K.G.; Duerfeldt, A.S.; Hu, J.; Xu, Q.; Ma, J.X.
New PPARα Agonist A190-Loaded Microemulsion for Chemotherapy-Induced Peripheral Neuropathy
Pangeni, R.; Poudel, S.; Herz, S.M.; Berkbigler, G.; Duerfeldt, A.S.; Damaj, I.M.; Xu, Q.
Semisynthetic Tetramate-Containing Fungal Metabolites with Activity against Trichomonas vaginalis and Mycoplasma genitalium
Peramuna, T.; Wood, G.E.; Hu, Z.; Wendt, K.L.; Aguila, L.K.T.; Kim, C.M.; Duerfeldt, A.S.; Cichewicz, R.H.
Design and Assessment of First-Generation Heterobifunctional PPARα/STING Modulators
Hu, B.; Cui, Y.; Lee, J.J.; Ma, J.X.; Duerfeldt, A.S.
Guiding the Way: Traditional Medicinal Chemistry Inspiration for Rational Gram-Negative Drug Design
Stoorza, A.M. and Duerfeldt, A.S.
Design, Synthesis, and Structure-Activity Relationships of Biaryl Anilines as Subtype-Selective PPAR-alpha Agonists
Lee, J.J.; Hu, Z.; Wang, Y.A.; Nath, D.; Liang, W.; Cui, Y.; Ma, J.X.; Duerfeldt, A.S.
The cGAS-STING Pathway in Diabetic Retinopathy and Age-related Macular Degeneration
Hu, B; Ma, J.X.; Duerfeldt, A.S.
Structure–Uptake Relationship Studies of Oxazolidinones in Gram-Negative ESKAPE Pathogens
Hu, Z.; Leus, I.V.; Chandar, B.; Sherborne, B.S.; Avila, Q.P.; Rybenkov, V.V.; Zgurskaya, H.I.; Duerfeldt, A.S.
Property Space Mapping of Pseudomonas aeruginosa Permeability to Small Molecules
Leus, I.V.; Weeks, J.W.; Bonifay, V.; Shen, Y.; Yang, L.; Cooper, C.J.; Nash, D.; Duerfeldt, A.S.; Smith, J.C.; Parks, J.M.; Rybenkov, V.V.; Zgurskaya, H.I.
CpxA Phosphatase Inhibitor Activates CpxRA and Is a Potential Treatment for Uropathogenic Escherichia coli in a Murine Model of Infection
Fortney, K.R.; Smith, S.N.; van Rensburg, J.J.; Brothwell, J.A.; Gardner, J.J.; Katz, B.P.; Ahsan, N.; Duerfeldt, A.S.; Mobley, H.L.T.; Spinola, S.M.
Identification of ClpP Dual Isoform Disruption as an Antisporulation Strategy for Clostridioides difficile
Bishop, C.E.; Shadid, T.M.; Lavey N.P.; Kempher, M.L.; Ballard, J.D.; Duerfeldt, A.S.
Small Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases
Dou, X.; Duerfeldt, A.S.
Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders
Dou, X.; Nath, D.; Shin, H.; Nurmemmedov, E.; Bourne, P.C.; Ma, J.X.; Duerfeldt, A.S.
First-Generation Structure-Activity Relationship Studies of 2,3,4,9-Tetrahydro-1H-carbazole-1-amines and CpxA Phosphatase Inhibitors
Li. Y.; Gardner, J.J.; Fortney, K.R.; Leus, I.V.; Bonifay, V.; Zgurskaya, H.I.; Pletnev, A.A.; Zhang, Z.Y.; Gribble, G.W.; Spinola, S.M.; Duerfeldt, A.S.
Clostridium difficile ClpP Homologues are Capable of Uncoupled Activity and Exhibit Different Levels of Susceptibility to Acyldepsipeptide Modulation
Lavey, N.P.; Shadid, T.; Ballard, J.D.; Duerfeldt, A.S.
Structure-Guided Evolution of a 2-Phenyl-4-Carboxyquinoline Chemotype into PPARα Selective Agonists: New Leads for Oculovascular Conditions
Dou, X.; Nath, D.; Shin, H.; Ma, J.X.; Duerfeldt, A.S.
Structure-Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 to Optimize Paralog-Specific Binding
Que, N.L.S.; Crowley, V.M.; Duerfeldt, A.S.; Zhao, J.; Kent, C.N.; Blagg, B.S.J.; Gewirth, D.T.
Consequences of Depsipeptide Substitution on the ClpP Activation Activity of Antibacterial Acyldepsipeptides
Li, Y.; Lavey, N.P.; Coker, J.A.; Knobbe, J.E.; Truong, D.C.; Yu, H.; Lin, Y.S.; Nimmo, S.I.; Duerfeldt, A.S.
Recent Advances Towards Rational Antibacterial Discovery: Addressing Permeation and Efflux
Avila, Q.P.; Zgurskaya, H.I.; Duerfeldt, A.S.
Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease P
Lavey, N.P.; Coker, J.A.; Ruben, E.A.; Duerfeldt, A.S.
Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold
Crowley, V.M.; Khandelwal, A.; Mishra, S.; Stothert, A.R.; Huard, D.J.E.; Zhao, J.; Muth, A.; Duerfeldt, A.S.; Kizzian, J.L.; Lieberman, R.L.; Dickey, C.A.; Blagg, B.S.J.
Grp94 Delivers Gamma-Aminobutyric Acid Type A (GABA) Receptors to HRD1-Mediated Endoplasmic Reticulum-Associated Degradation
Di, X.J.; Wang, Y.J.; Han, D.Y.; Fu, Y.L.; Duerfeldt, A.S.; Blagg, B.S.J.; Mu, T.W.
Cycloadditions of Noncomplementary Substituted 1,2,3-Triazines
Anderson, E.A.; Duerfeldt, A.S.; Zhu, K.; Glinkerman, C.M.; Boger, D.L.
Stereoselective Synthesis of (-)-Pyrimidoblamic Acid and P-3A
Duerfeldt, A.S.; Boger, D.L.
Fundamental Relationship between Hydrophobic Properties and Biological Activity for the Duocarmycin Class of DNA Alkylating Antitumor Drugs: Hydrophobic Binding-Driven-Bonding
Wolfe, A.L.; Duncan, K.K.; Lajiness, J.P.; Zhu, K.; Duerfeldt, A.S.; Boger, D.L.
Glucose-Regulated Protein 94 Triage of Mutant Myocilin through Endoplasmic Reticulum-Associated Degradation Subverts a More Efficient Autophagic Clearance Mechanism
Suntharalingam, A.; Abisambra, J.F.; O’Leary, J.C.; Koren III, J.; Zhang. B.; Kuk Joe, M.; Blair, L.J.; Hill, S.E.; Jinwal, U.K.; Cockman, M.; Duerfeldt, A.S.; Tomarev, S.; Blagg, B.S.J.; Lieberman, R.L.; Dickey, C.A.
J. Biol. Chem., 2012, 287, 40661.
Development of a Grp94 Inhibitor
Duerfeldt, A.S.; Peterson, L.B.; Maynard, J.C.; Ng, C.L.; Eletto, D.; Ostrovsky, O.; Shinogle, H.E.; Moore, D.S.; Argon, Y.; Nicchitta, C.V.; Blagg, B.S.J.
Synthesis and Biological Evaluation of Arylated Novobiocin Analogs as Hsp90 Inhibitors
Kusuma, B.R.; Duerfeldt, A.S.; Blagg, B.S.J.
Hsp90 Inhibition: Elimination of Shock and Stress
Duerfeldt, A.S.; Blagg, B.S.J.
Design, Synthesis, and Biological Activity of Bicyclic Radester Analogs as Hsp90 Inhibitors
Jadhav, V.; Duerfeldt, A.S.; Blagg, B.S.J.
Design, Synthesis and Biological Evaluation of Conformationally Constrained cis-Amide Hsp90 Inhibitors
Duerfeldt, A.S.; Brandt, G.E.L.; Blagg, B.S.J.
Page updated
Google Sites
Report abuse